GoldenGolden
Advanced Search
SV Health Investors

SV Health Investors

A venture capital firm in Massachusetts that focuses on biotechnology and healthcare industry.

SV Health Investors is a venture capital firm in Massachusetts that focuses on biotechnology and healthcare industry. Founded 1993 in Boston, Massachusetts, United States, it invests in debt, early stage ventures, late stage ventures, series B, series A, and series D rounds. Its portfolio companies include Xilio Therapeutics, EBT Medical, Ervaxx, Healthify, Clarify Medical, Bardy Diagnostics, CSA Medical, Rheostat Therapeutics, Ribometrix, and Urgent Team Holdings, Inc. As of April 2020, SV Health Investors has made 216 investments. Their most recent investment was on March 2, 2020, when Xilio Therapeutics raised $100.5M. V Health Investors has had 38 exits, the most notable of which include Bicycle Therapeutics, Avrobio, and Sutro Biopharma. The company has raised seven funds, their latest being SV7 Growth Fund.

Timeline

Associated investment funds

People

Name
Role
LinkedIn

David Milne

Managing Partner

Jacqueline Grant

Senior Associate

Michael Balmuth

Managing Partner

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

EBT Medical

Ervaxx

Healthify

Xilio Therapeutics

News

Title
Author
Date
Publisher
Description
BioSpace
June 22, 2021
BioSpace
Alchemab Therapeutics today announced the appointment of Douglas A. Treco, PhD as Chief Executive Officer.
May 10, 2021
BioSpace
Therini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic - read this article along with other careers information, tips and advice on BioSpace
The Dementia Discovery Fund
May 5, 2021
www.prnewswire.com:443
/PRNewswire/ -- The Dementia Discovery Fund (DDF), the venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic...
Mark Terry
April 15, 2021
BioSpace
Several companies launched with Series A financing rounds today. Read on for details.
April 15, 2021
BioSpace
Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics - read this article along with other careers information, tips and advice on BioSpace
Health Payment Systems
February 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- Health Payment Systems, Inc. (HPS, the "Company"), an innovator in the healthcare payments space, today announced that SV Health Investors, LLC...
Amirah Al Idrus
November 23, 2020
FierceBiotech
Cell therapies have seen success in some blood cancers, but the same can't be said for solid tumors. Several biotechs have sprung up to close that gap in different ways, but Catamaran Bio thinks single "linchpin" approaches won't be enough. Instead, it's taking a multipronged approach shepherded by a team of cell therapy and biopharma veterans.
FinSMEs
November 23, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Mattha Busby
November 8, 2020
the Guardian
Kate Bingham speaking on television in September. Photograph: ITV/Rex/Shutterstock
Mattha Busby
November 8, 2020
the Guardian
Report claims Kate Bingham's venture capital firm has invested in companies developing Covid-19 antibody cocktails

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.